TB-420

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameTB-420
Drug Alias NameTB-420
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Source of cells > iPSC-derivedCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionGlypican-3 modulators
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTherabest INC
China Registration ClassN/A

Develop Information

Active CompaniesTherabest INCVigencell Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A